| Literature DB >> 27042179 |
Denise Tostes Oliveira1, Diego Mauricio Bravo-Calderón1, Gustavo Amaral Lauand1, Agnes Assao1, José-Manuel Suárez-Peñaranda2, Mario Pérez-Sayáns3, Abel García-García3, Aparecido Nilceu Marana4, Suely Nonogaki5, José Roberto Pereira Lauris6, Luiz Paulo Kowalski7.
Abstract
Background. The beta-2 adrenergic receptor is expressed by neoplastic cells and is correlated with a wide spectrum of tumor cell mechanisms including proliferation, apoptosis, angiogenesis, migration, and metastasis. Objectives. The present study aimed to analyze the expression of the beta-2 adrenergic receptor (β2-AR) in tumor-free surgical margins of oral squamous cell carcinomas (OSCC) and at the invasive front. Sixty-two patients diagnosed with OSCC, confirmed by biopsy, were selected for the study. The clinicopathological data and clinical follow-up were obtained from medical records and their association with β2-AR expression was verified by the chi-square test or Fischer's exact test. To verify the correlation of β2-AR expression in tumor-free surgical margins and at the invasive front of OSCCs, Pearson's correlation coefficient test was applied. Results. The expression of β2-AR presented a statistically significant correlation between the tumor-free surgical margins and the invasive front of OSCC (r = 0.383; p = 0.002). The immunohistochemical distribution of β2-AR at the invasive front of OSCC was also statistically significant associated with alcohol (p = 0.038), simultaneous alcohol and tobacco consumption (p = 0.010), and T stage (p = 0.014). Conclusions. The correlation of β2-AR expression in OSCC and tumor-free surgical margins suggests a role of this receptor in tumor progression and its expression in normal oral epithelium seems to be constitutive.Entities:
Year: 2016 PMID: 27042179 PMCID: PMC4793135 DOI: 10.1155/2016/3531274
Source DB: PubMed Journal: J Oncol ISSN: 1687-8450 Impact factor: 4.375
Figure 1Correlation of the averages of β2-AR immunoexpression in OSCC specimens. The lines correspond to the cut-off point that classifies the invasive tumor fronts (green line) and the surgical margins (blue line) as exhibiting weak/negative (averages 0.62 to 23.86) or moderate/strong (averages 25.99 to 79.63) β2-AR expression.
Figure 2Expression pattern of β2-AR in OSCC specimens. (a and b) OSCC with strong expression of β2-AR in both surgical margin and invasive front of tumor. (c and d) OSCC with weak expression of β2-AR in both surgical margin and invasive front of tumor. (e and f) OSCC with reduced expression of β2-AR at the invasive front of the tumor when compared to surgical margin. Note the membranous and/or cytoplasmic expression pattern of β2-AR in immunostained cells (a, b, c, d, e, and f: immunohistochemistry β2-AR, original magnification ×400).
Association between clinical parameters and β2-AR expression in 62 patients with oral squamous cell carcinoma.
| Variable | Beta-2 adrenergic receptor | ||||||
|---|---|---|---|---|---|---|---|
| Tumor-free margin | Invasive tumor front | ||||||
| Weak | Moderate/strong |
| Weak/negative | Moderate/strong |
| ||
|
|
|
|
| ||||
| Gender | Male | 8 (66.7) | 44 (88) | 0.091 | 31 (86.1) | 21 (80.8) | 0.729 |
| Female | 4 (33.3) | 6 (12) | 5 (13.9) | 5 (19.2) | |||
|
| |||||||
| Ethnic group | White | 10 (83.3) | 45 (90) | 0.612 | 33 (91.7) | 22 (84.6) | 0.439 |
| Not white | 2 (16.7) | 5 (10) | 3 (8.3) | 4 (15.4) | |||
|
| |||||||
| Age | ≤58 years | 8 (66.7) | 25 (50) | 0.299 | 22 (61.1) | 11 (42.3) | 0.143 |
| >58 years | 4 (33.3) | 25 (50) | 14 (38.9) | 15 (57.7) | |||
|
| |||||||
| Tobacco# | Yes | 11 (100) | 42 (93.3) | 0.999 | 31 (100) | 22 (88) | 0.083 |
| No | 0 (0) | 3 (6.7) | 0 (0) | 3 (12) | |||
|
| |||||||
| Alcohol# | Yes | 10 (90.9) | 32 (69.6) | 0.256 | 27 (84.4) | 15 (60) |
|
| No | 1 (9.1) | 14 (30.4) | 5 (15.6) | 10 (40) | |||
|
| |||||||
| Tobacco + alcohol# | Yes | 10 (90.9) | 29 (64.4) | 0.144 | 26 (83.9) | 13 (52) |
|
| No | 1 (9.1) | 16 (35.6) | 5 (16.1) | 12 (48) | |||
|
| |||||||
| T stage | T1/T2 | 6 (50) | 28 (56) | 0.708 | 15 (41.7) | 19 (73.1) |
|
| T3/T4 | 6 (50) | 22 (44) | 21 (58.3) | 7 (26.9) | |||
|
| |||||||
| N stage | N+ | 6 (50) | 24 (48) | 0.901 | 18 (50) | 12 (46.2) | 0.765 |
| N0 | 6 (50) | 26 (52) | 18 (50) | 14 (53.8) | |||
|
| |||||||
| Clinical stage | II | 3 (25) | 16 (32) | 0.74 | 9 (25) | 10 (38.5) | 0.257 |
| III/IV | 9 (75) | 34 (68) | 27 (75) | 16 (61.5) | |||
|
| |||||||
| Recurrence## | Yes | 6 (50) | 20 (40) | 0.528 | 17 (47.2) | 9 (34.6) | 0.321 |
| No | 6 (50) | 30 (60) | 19 (52.8) | 17 (65.4) | |||
|
| |||||||
| Metastases | Yes | 0 (0) | 1 (2) | 0.999 | 0 (0) | 1 (3.8) | 0.419 |
| No | 12 (100) | 49 (98) | 36 (100) | 25 (96.2) | |||
|
| |||||||
| Second primary tumor | Yes | 1 (8.3) | 8 (16) | 0.675 | 5 (13.9) | 4 (15.4) | 0.999 |
| No | 11 (91.7) | 42 (84) | 31 (86.1) | 22 (84.6) | |||
N: number of cases; p: p value obtained by chi-square test or Fisher's exact test; #excluding patients with lost records; ##local and/or regional recurrence; statistically significant result.
Association between histopathological parameters and β2-AR expression in 62 patients with oral squamous cell carcinoma.
| Beta-2 adrenergic receptor | |||||||
|---|---|---|---|---|---|---|---|
| Variable | Tumor-free margin | Invasive tumor front | |||||
| Weak | Moderate/strong |
| Weak/negative | Moderate/strong |
| ||
|
|
|
|
| ||||
| Malignancy grading | M. diff. | 10 (83.3) | 44 (88) | 0.645 | 31 (86.1) | 23 (88.5) | 0.999 |
| L. diff. | 2 (16.7) | 6 (12) | 5 (13.9) | 3 (11.5) | |||
|
| |||||||
| Vascular embolization | Yes | 9 (75) | 26 (52) | 0.149 | 23 (63.9) | 12 (46.2) | 0.165 |
| No | 3 (25) | 24 (48) | 13 (36.1) | 14 (53.8) | |||
|
| |||||||
| Perineural infiltration | Yes | 9 (75) | 36 (72) | 0.999 | 24 (66.7) | 21 (80.8) | 0.219 |
| No | 3 (25) | 14 (28) | 12 (33.3) | 5 (19.2) | |||
|
| |||||||
| Muscular infiltration | Yes | 11 (91.7) | 43 (86) | 0.999 | 31 (86.1) | 23 (88.5) | 0.999 |
| No | 1 (8.3) | 7 (14) | 5 (13.9) | 3 (11.5) | |||
|
| |||||||
| Bone infiltration# | Yes | 1 (8.3) | 5 (10.2) | 0.999 | 5 (14.3) | 1 (3.8) | 0.227 |
| No | 11 (91.7) | 44 (89.8) | 30 (85.7) | 25 (96.2) | |||
|
| |||||||
| Lymph node involvement |
| 4 (33.3) | 26 (52) | 0.245 | 18 (50) | 12 (46.2) | 0.765 |
|
| 8 (66.7) | 24 (48) | 18 (50) | 14 (53.8) | |||
N: number of cases; p: p value obtained by chi-square test or Fisher's exact test; M. diff.: more differentiated tumor; L. diff.: less differentiated tumor; #excluding patients with lost records.